Astrana Health Inc. (ASTH)

Over the past six months, Astrana Health's stock price has been impacted by several events, including a 22.6% decline over a single week prior to November 10, 2025. The company reported a significant EPS shortfall in its third-quarter 2025 earnings, despite revenue slightly exceeding forecasts. Following these results, TD Cowen, Barclays, and BTIG Research lowered their price targets for ASTH, while Needham & Company LLC initiated coverage with a "buy" rating. Weiss Ratings reiterated a "sell" rating. The stock continued to show volatility, with shares gapping down on January 27, 2026. As of January 29, 2026, the share price was down 39.14% from the previous year. On February 2, 2026, CEO and President Brandon Sim exercised options for 21,334 shares. Overall, Astrana Health's stock has underperformed both the US Healthcare industry and the broader US Market over the past year.

Specific details regarding the demand seasonality for Astrana Health's products and services are not explicitly provided in the available information. However, the company has demonstrated strong and recently accelerated demand, with significant revenue growth over the last two years and in the most recent quarter. Analysts anticipate continued healthy revenue growth, suggesting sustained market success for its offerings.

Astrana Health, Inc. is a patient-centered, physician-centric integrated population health management company focused on providing coordinated, outcomes-based medical care in a cost-effective manner, particularly for senior patients and individuals with multiple chronic conditions. The company operates within the Healthcare sector, specializing in healthcare providers and services, emphasizing value-based care models. Astrana Health's operations are structured into three reportable segments: Care Partners, Care Delivery, and Care Enablement. The Care Delivery segment manages approximately 60 healthcare facilities across California, Nevada, and Texas, offering a range of services. The Care Enablement segment provides a proprietary technology platform. The Care Partners segment generates the majority of the company's revenue.

Astrana Health's geographic footprint primarily includes its approximately 60 healthcare facilities located across California, Nevada, and Texas. The company's targeted geographic operations span across the United States, serving over 800,000 patients annually within these communities.

Astrana Health is described as a patient-centered, physician-centric company focused on delivering high-quality medical care, and analysts generally hold a "Moderate Buy" rating for the company. The acquisition of Prospect Health in July 2025 could positively impact its strategic direction and market perception. Leadership appointments in 2025 indicate a strategic focus on enhancing the company's AI capabilities and value-based care platform. No specific events negatively impacting Astrana Health's brand reputation in the past year were explicitly found, beyond financial performance and stock price fluctuations.

Astrana Health's ownership structure is significantly influenced by institutional investors, who held 67.35% of shares as of July 23, 2025. Key institutional shareholders include BlackRock, Inc., Vanguard Group Inc., State Street Corp, Fmr Llc, and Dimensional Fund Advisors Lp. Mutual funds increased their stake to 47.09% in April 2025. Insider holdings accounted for 4.59% in April 2025, with a slight decrease in insider ownership concentration over the 90 days ending January 29, 2026, to 59.64% of the company's equity base. The largest insider shareholders include Albert Waichow Young, Physicians Of California, and Thomas S. Lam. CEO and President Brandon Sim directly owned 1,045,329 shares as of February 2, 2026.